A Phase 3 interventional study of Ventavis (Iloprost, BAYQ6256) in Hypertension, Pulmonary, sponsored by Bayer. Completed at 16 sites in 7 countries. Open to participants aged 18 Years to 71 Years. Per ClinicalTrials.gov, last updated 2010-04-20.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.
This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
1,119 studies on the registry are indexed under Hypertension, Pulmonary; 236 are open to participants now.
This study's enrollment of 71 is above the median of 35 across 659 interventional studies indexed under Hypertension, Pulmonary.
Browse Hypertension, Pulmonary studies →Bayer is the lead sponsor of 1,674 studies on the registry; 54 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 130 (61%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ventavis (Iloprost, BAYQ6256)
Inhaled iloprost
Adverse events
Time frame: Throughout the whole study
Tolerability of treatment
Time frame: Over a minimum of 24 months
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iloprost